Lauren A Zimmaro1, Sandra E Sephton1,2, Chelsea J Siwik1, Kala M Phillips1, Whitney N Rebholz3, Helena C Kraemer4, Janine Giese-Davis5,6,7, Liz Wilson2,3, Jeffrey M Bumpous2,3, Elizabeth D Cash1,2,3. 1. Department of Psychological and Brain Sciences, University of Louisville, Louisville, Kentucky. 2. James Graham Brown Cancer Center, Louisville, Kentucky. 3. Department of Otolaryngology-Head and Neck Surgery and Communicative Disorders, University of Louisville School of Medicine, Louisville, Kentucky. 4. Department of Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, California. 5. Alberta Health Services Center Care (Holy Cross Site), Calgary, Alberta, Canada. 6. Division of Psychosocial Oncology, Department of Oncology, Faculty of Medicine, University of Calgary, Alberta, Canada. 7. Department of Psychology, University of Calgary, Calgary, Alberta, Canada.
Abstract
BACKGROUND: Head and neck cancers are associated with high rates of depression, which may increase the risk for poorer immediate and long-term outcomes. Here it was hypothesized that greater depressive symptoms would predict earlier mortality, and behavioral (treatment interruption) and biological (treatment response) mediators were examined. METHODS: Patients (n = 134) reported depressive symptomatology at treatment planning. Clinical data were reviewed at the 2-year follow-up. RESULTS: Greater depressive symptoms were associated with significantly shorter survival (hazard ratio, 0.868; 95% confidence interval [CI], 0.819-0.921; P < .001), higher rates of chemoradiation interruption (odds ratio, 0.865; 95% CI, 0.774-0.966; P = .010), and poorer treatment response (odds ratio, 0.879; 95% CI, 0.803-0.963; P = .005). The poorer treatment response partially explained the depression-survival relation. Other known prognostic indicators did not challenge these results. CONCLUSIONS: Depressive symptoms at the time of treatment planning predict overall 2-year mortality. Effects are partly influenced by the treatment response. Depression screening and intervention may be beneficial. Future studies should examine parallel biological pathways linking depression to cancer survival, including endocrine disruption and inflammation. Cancer 2018;124:1053-60.
BACKGROUND: Head and neck cancers are associated with high rates of depression, which may increase the risk for poorer immediate and long-term outcomes. Here it was hypothesized that greater depressive symptoms would predict earlier mortality, and behavioral (treatment interruption) and biological (treatment response) mediators were examined. METHODS:Patients (n = 134) reported depressive symptomatology at treatment planning. Clinical data were reviewed at the 2-year follow-up. RESULTS: Greater depressive symptoms were associated with significantly shorter survival (hazard ratio, 0.868; 95% confidence interval [CI], 0.819-0.921; P < .001), higher rates of chemoradiation interruption (odds ratio, 0.865; 95% CI, 0.774-0.966; P = .010), and poorer treatment response (odds ratio, 0.879; 95% CI, 0.803-0.963; P = .005). The poorer treatment response partially explained the depression-survival relation. Other known prognostic indicators did not challenge these results. CONCLUSIONS:Depressive symptoms at the time of treatment planning predict overall 2-year mortality. Effects are partly influenced by the treatment response. Depression screening and intervention may be beneficial. Future studies should examine parallel biological pathways linking depression to cancer survival, including endocrine disruption and inflammation. Cancer 2018;124:1053-60.
Authors: Sean T Massa; Nosayaba Osazuwa-Peters; Kara M Christopher; Lauren D Arnold; Mario Schootman; Ronald J Walker; Mark A Varvares Journal: Oral Oncol Date: 2016-12-18 Impact factor: 5.337
Authors: Megan Dann Fesinmeyer; Vivek Mehta; David Blough; Lauri Tock; Scott D Ramsey Journal: Int J Radiat Oncol Biol Phys Date: 2010-02-03 Impact factor: 7.038
Authors: James C Coyne; Thomas F Pajak; Jonathan Harris; Andre Konski; Benjamin Movsas; Kian Ang; Deborah Watkins Bruner Journal: Cancer Date: 2007-12-01 Impact factor: 6.860
Authors: Eric Adjei Boakye; Nosayaba Osazuwa-Peters; Kahee A Mohammed; Sai Challapalli; Paula Buchanan; Thomas E Burroughs; Mark A Varvares Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2019-08-23 Impact factor: 4.328
Authors: Femke Jansen; Irma M Verdonck-de Leeuw; Pim Cuijpers; C René Leemans; Tim Waterboer; Michael Pawlita; Chris Penfold; Steven J Thomas; Andrea Waylen; Andrew R Ness Journal: Psychooncology Date: 2018-07-23 Impact factor: 3.894
Authors: Axel Sahovaler; Tommaso Gualtieri; David Palma; Kevin Fung; S Danielle MacNeil; John Yoo; Anthony Nichols Journal: Acta Otorhinolaryngol Ital Date: 2021-02 Impact factor: 2.124
Authors: Jenna L Adamowicz; Alan Christensen; M Bryant Howren; Aaron T Seaman; Nicholas D Kendell; Shylo Wardyn; Nitin A Pagedar Journal: J Rural Health Date: 2021-03-15 Impact factor: 5.667